{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T23:37:03Z","timestamp":1726184223814},"reference-count":44,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":4406,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1997,4]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> The results of an intensive treatment program for patients 16\u201360 yr of age with <jats:italic>de novo<\/jats:italic> acute myeloid leukemia are presented. The patients were given conventional induction treatment with daunorubicin and cytarabine. Patients not entering complete remission (CR) after 1 course of daunorubicin\/cytarabine were given 1 course of amsacrine\/etoposide\/cytarabine. Those entering complete remission received 3 consolidation courses using mitoxantrone, etoposide, amsacrine and cytarabine. One hundred and eighteen patients were enrolled. Complete remission was attained after 1\u20132 courses in 90 patients (76%). Another 6 patients reached CR after 3\u20134 induction courses for a total CR rate of 81%. If feasible, patients were offered either allogeneic or unpurged autologous bone marrow transplantation. Twenty\u2010four patients underwent allogeneic bone marrow transplantation; 15 in first remission, 8 in second remission, 1 in early relapse. Thirty patients below 56 yr of age underwent autologous bone marrow transplantation in first remission. The overall probability of survival at 4 yr was 34%, and for patients below 40 yr of age 50%. Leukemia\u2010free survival was 35% for the whole cohort of patients; 52% for patients below 40 yr of age. Patients undergoing allogeneic or autologous bone marrow transplantation in first remission had an overall survival of 86% and 47%, respectively, while the probability of leukemia\u2010free survival in these groups was 87% vs. 40% at 4 yr. The CR rate and long\u2010term results of this intensive treatment program compare favorably with other recent studies using intensive consolidation with allogeneic or autologous bone marrow transplantation or high dose cytarabine.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1997.tb01660.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T08:04:43Z","timestamp":1279440283000},"page":"233-240","source":"Crossref","is-referenced-by-count":6,"title":["Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for <i>de novo<\/i> acute myeloid leukemia"],"prefix":"10.1111","volume":"58","author":[{"given":"Anders","family":"Wahlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorentz","family":"Brinch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"H\u00f6rnsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stein A.","family":"Evensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"\u00d6berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hedenus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900090106"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311402"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.12.1583"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1991.tb00547.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.8.1924.1924"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00610.x"},{"issue":"1","key":"e_1_2_1_8_2","first-page":"434a","article-title":"Meta\u2010analysis of randomized trials of idarubicin (IDAR) or mitozantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukemia (AML)","volume":"86","author":"Wheatley K.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-3-460"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-4-620"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.5.813"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1988.tb16756.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","article-title":"Bone marrow transplantation following a new busulfan and cyclophosphamide, regimen","volume":"70","author":"Tutschka PJ","year":"1987","journal-title":"Blood"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0308-2261(86)80004-2"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820301)49:5<916::AID-CNCR2820490515>3.0.CO;2-L"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197511)36:5<1560::AID-CNCR2820360504>3.0.CO;2-5"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950060311"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30257-0"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-94-6-753"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.V77.7.1429.1429","article-title":"High\u2010dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults","volume":"77","author":"Phillips GL","year":"1991","journal-title":"Blood"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.8.1666.1666"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1103"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.560"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.10.2520.2520"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.5.1710.1710"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19861015)58:8<1603::AID-CNCR2820580804>3.0.CO;2-S"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04253.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(91)90124-C"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409114141"},{"key":"e_1_2_1_33_2","first-page":"562","article-title":"A prospective evaluation of the roles of allogeneic marrow transplantation and low\u2010dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study","volume":"9","author":"Hewlett J","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201163260303"},{"key":"e_1_2_1_35_2","first-page":"13","article-title":"Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time \u2013 a report of the acute leukemia working party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"17","author":"Frassoni F","year":"1996","journal-title":"Bone Marrow Trans"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91508-3"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.8.1606.1606"},{"key":"e_1_2_1_38_2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.V76.3.480.480","article-title":"High\u2010dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia","volume":"76","author":"McMillan AK","year":"1990","journal-title":"Blood"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501263320403"},{"key":"e_1_2_1_40_2","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1182\/blood.V84.11.3810.bloodjournal84113810","article-title":"One hundred twenty\u2010five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10\u2010year single institution experience","volume":"84","author":"Laporte JP","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_41_2","first-page":"1698","article-title":"Improved outcome for high\u2010risk acute myeloid leukemia patients using autologous bone marrow transplantion and monoclonal antibody\u2010purged bone marrow","volume":"83","author":"Selvaggi KJ","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03025.x"},{"key":"e_1_2_1_43_2","first-page":"924","article-title":"Are patients with acute leukemia, alive and well 2 years post bone marrow transplantation cured? A European survey","volume":"8","author":"Frassoni F","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_1_44_2","first-page":"78","article-title":"Allogeneic versus autologous marrow transplantation for patients with acute myeeloid leukemia in first marrow remission. An update of the Genoa experience with 159 patients","volume":"6","author":"Carella AM","year":"1992","journal-title":"Leukemia"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.2.575.575"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1997.tb01660.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1997.tb01660.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T19:09:39Z","timestamp":1698433779000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1997.tb01660.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,4]]}},"alternative-id":["10.1111\/j.1600-0609.1997.tb01660.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1997.tb01660.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,4]]}}}